ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

WVE vs DSGN // OPERATING MARGIN

Wave Life Sciences Inc. (NASDAQ) VS. Design Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: WVE 2 — DSGN 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WVE VS. DSGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC WVE DSGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -32.10% -2.90 DSGN /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -7.88% — TIE /fcf-yield <GO>
Operating Margin ACTIVE -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -60.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.85 26.00 -25.15 DSGN /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.6 47.2 +3.40 WVE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $715.9M $692.2M $23.8M WVE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR WVE REV DSGN REV WVE GROSS % DSGN GROSS % WVE FCF DSGN FCF
FY 2025 $42.7M $0 — — -$188.2M -$54.6M
FY 2024 $108.3M $0 — — -$152.0M -$43.4M
FY 2023 $113.3M $0 — — -$19.4M -$58.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WVE // BETA —
DSGN // BETA —